Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Insulin

<< Previous

Bullboard Posts

Next >>

Comment by Danny1082Manon May 26, 2020 10:10pm

231 Views

Post# 31076091

RE:Insulin

I disagree. The TG redux in the insulin use mentioned in the thesis is well known and was not the surprise. It was the dosing at the beginning of the trial that was. Most those facing Diabetes are not insulin dependent. They still want to show TG redux AND hemoglobin redux with Capre

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery